Literature DB >> 9951757

Normothermic cardiopulmonary bypass increases heparin requirements necessary to maintain anticoagulation.

M H Ereth1, B R Fisher, D J Cook, G A Nuttall, T A Orszulak, W C Oliver.   

Abstract

OBJECTIVE: With the practice of warm cardiopulmonary bypass (CPB) at our institution we have observed an apparent increase in heparin requirements. CPB temperature predictability affects pharmacokinetics and differences in drug metabolism can be expected. We hypothesized that heparin requirements would increase with increasing CPB temperature.
METHODS: Following Institutional Review Board approval, we reviewed the charts of 354 patients undergoing primary coronary artery bypass graft surgery. We recorded patient demographic data, CPB duration, heparin requirements, and temperature during CPB. CPB was conducted between 24 degrees C and 37 degrees C. The Spearman's correlation coefficient, Pearson chi-square, and rank-sum tests were used for data analysis.
RESULTS: Core temperature during CPB correlated with heparin requirements (r = 0.13, p < 0.02). However, CPB duration was shorter in warm patients than in cold patients (r = -0.455, p < 0.0001). Additional heparin requirements adjusted for duration of CPB (units/minute) were also significantly greater in the warm group (p = 0.018).
CONCLUSIONS: Maintenance of adequate heparin anticoagulation during CPB is clinically important. Warm CPB patients required more heparin per minute than those undergoing cold CPB. More frequent assessment of anticoagulation and administration of additional heparin should be considered in patients undergoing warm CPB.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9951757     DOI: 10.1023/a:1009987505590

Source DB:  PubMed          Journal:  J Clin Monit Comput        ISSN: 1387-1307            Impact factor:   2.502


  20 in total

1.  The effect of warm heart surgery on postoperative bleeding.

Authors:  T M Yau; S Carson; R D Weisel; J Ivanov; Z Sun; R Yu; M F Glynn; S J Teasdale
Journal:  J Thorac Cardiovasc Surg       Date:  1992-06       Impact factor: 5.209

2.  Kinetics of the anticoagulant effect of heparin.

Authors:  J W Estes
Journal:  JAMA       Date:  1970-06-01       Impact factor: 56.272

3.  Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols.

Authors:  B S Bull; R A Korpman; W M Huse; B D Briggs
Journal:  J Thorac Cardiovasc Surg       Date:  1975-05       Impact factor: 5.209

4.  Heparin kinetics: variables related to disposition and dosage.

Authors:  R J Cipolle; R D Seifert; B A Neilan; D E Zaske; E Haus
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

5.  The influence of hypothermia on the disposition of fentanyl--human and animal studies.

Authors:  G Koren; C Barker; G Goresky; D Bohn; G Kent; J Klein; S M MacLeod; W D Biggar
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding.

Authors:  G P Gravlee; A T Rogers; L M Dudas; R Taylor; R C Roy; L D Case; M Triscott; C W Brown; L J Mark; A R Cordell
Journal:  Anesthesiology       Date:  1992-03       Impact factor: 7.892

7.  Hemodynamic and hormonal responses to hypothermic and normothermic cardiopulmonary bypass.

Authors:  J J Lehot; J Villard; H Piriz; D M Philbin; P Y Carry; G Gauquelin; B Claustrat; G Sassolas; J Galliot; S Estanove
Journal:  J Cardiothorac Vasc Anesth       Date:  1992-04       Impact factor: 2.628

8.  Physiology and pharmacology of hypothermia.

Authors:  K C Wong
Journal:  West J Med       Date:  1983-02

9.  Greater neuromuscular blocking potency of atracurium during hypothermic than during normothermic cardiopulmonary bypass.

Authors:  C Diefenbach; M Abel; W Buzello
Journal:  Anesth Analg       Date:  1992-11       Impact factor: 5.108

10.  Kinetics of intravenously administered heparin in normal humans.

Authors:  C A de Swart; B Nijmeyer; J M Roelofs; J J Sixma
Journal:  Blood       Date:  1982-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.